Search Results - Boards

Ticker	Board	Posts	Last Post	Category
VNE	Veoneer, Inc.	1	4 years ago	Automotive and Transportation
VNET	21 Vianet Group	56	1 month ago	Internet - Information/Portals
AVNE	Aventura Equities Inc	38,908	3 years ago	Internet - Online Services
AVT	Avnet, Inc.	3	11 years ago	Electronics and components
	Avner Oil Exploation LP (fka AVOGF)	33	12 years ago	Delisted
	V-ONE CORP NEW (fka VNECQ)	31	15 years ago	Delisted

Play Episode

8min

Proactive - Interviews for investors

Light Science Technologies CEO on Injecta Fire Barrier solution to UK's unsafe cladding dilemma

Light Science Technologies Holdings PLC (AIM:LST) CEO Simon Deacon talked with Proactive's Stephen Gunnion about the significant opportunity surrounding the company’s Injecta Fire Barrier solution, particularly in light of ongoing fire safety issues in the UK’s residential building sector. Deacon highlighted that the UK still has more than 33,000 buildings between 11m and 18m in height, and over 11,000 high-risk buildings above 18m, that require urgent fire protection measures. He referenced a government estimate suggesting a potential £22 billion cost to address the cladding crisis, which has persisted since the Grenfell tragedy. The Injecta Fire Barrier, acquired in late 2023, offers what Deacon described as a "unique solution"—one that avoids facade removal by injecting fire-resistant material directly into cavities, providing over two hours of fire resistance. He said, "We're three times less in cost and much quicker to install than traditional methods." He noted the division secured £2.7 million in orders during 2024, performing strongly and receiving positive feedback for its efficiency and clean delivery. With an average order value over £500,000 and significant market scope, Deacon framed the opportunity as a scalable revenue driver for the group. The company is targeting £50 million in revenue over the next five years, with Injecta Fire Barrier expected to be a key growth driver. 👉 For more updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #FireSafety #BuildingSafety #InjectaFireBarrier #LightScienceTechnologies #GrenfellLegacy #PropertyInvestment #ConstructionInnovation #FireProtection #CladdingCrisis #UKHousingSafety #ProactiveInvestors #SimonDeacon #BuildingRegulations #RealEstateSafety #PassiveFireProtection

Proactive - Interviews for investors

Nextech3D.ai unveils AI-powered customer service chatbot, ushering new era of customer engagement

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to introduce the company’s latest innovation: an AI-powered customer service chat agent designed to enhance customer interactions and drive sales. This cutting-edge virtual assistant, integrated directly into Nextech3D.ai’s website, features advanced voice technology from Eleven Labs, enabling natural, human-like conversations. The AI chatbot is engineered to streamline customer support with a range of capabilities, including appointment scheduling, a dynamic knowledge base tailored to Nextech’s services, and seamless transitions to live representatives when needed. By leveraging artificial intelligence, Nextech aims to provide a frictionless, efficient, and engaging experience for its customers. Gappelberg emphasized that the adoption of AI chat agents marks a pivotal step in Nextech3D.ai’s evolution into an AI-first technology company, positioning it to compete at the highest level. The chatbot is not just a tool for customer engagement but also a powerful lead generation asset, automating appointment bookings and capturing high-quality leads to optimize service efficiency. By integrating this AI assistant, Nextech ensures that customers receive accurate, brand-aligned responses to their inquiries while maintaining the option for human support when necessary. With this move, Nextech3D.ai reaffirms its commitment to innovation and sets a new standard for AI-driven customer interactions. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #AmazonSellerCentral #3DModeling #AIPhotography #EcommerceInnovation #3DTechnology #LifestylePhotography #ProactiveInterviews #TechInnovation #AmazonPartners#proactiveinvestors #nextech3d.al

Proactive - Interviews for investors

Opioid-Free pain relief: AFT’s global expansion strategy

AFT Pharmaceuticals Ltd Managing Director Dr Hartley Atkinson talked with Proactive at the AIM's Small and Midcap Conference about the company's unique approach to drug development, its expanding global footprint, and what lies ahead in 2025. AFT Pharmaceuticals is focused on creating pharmaceuticals "with a difference," targeting unmet needs and reducing reliance on opioids. “We don’t sell anything we don’t believe in,” said Dr Atkinson, highlighting the importance of alternatives to opioid treatments. One of the company’s key analgesic products helps avoid opioid use — a particularly timely innovation in light of the global opioid crisis. Dr Atkinson discussed the company’s core markets, with a strong presence in New Zealand and Australia, generating approximately 150 million in revenue. AFT also maintains operations in Asia and now exports to around 80 countries. The company has experienced sustained growth, having quadrupled in size over the past decade and doubled in the last five years. AFT has established six new affiliates across regions including Singapore, Hong Kong, South Africa, Canada, the UK, and Europe. Looking ahead, the company plans several product launches across Australia and New Zealand and anticipates five drug launches in China — the world’s second-largest pharmaceutical market. “For us, that’s going to be an interesting journey,” Atkinson added. #AFTPharmaceuticals #OpioidAlternatives #PharmaceuticalInnovation #ChinaPharma #DrugDevelopment #HealthcareGrowth #ASXStocks #BiotechInvesting #GlobalHealthcare #PharmaExpansion

Proactive - Interviews for investors

EBR Systems nears FDA approval for CRT pacemaker

EBR Systems Inc Senior Vice President Andrew Shute talked with Proactive at the AIM maSmall and Midcap Conference about the company’s upcoming FDA decision for its leadless CRT pacemaker system. The device is designed to treat heart failure and represents the only leadless option in a market currently dominated by three players—with no direct competitor. Shute said, “We've developed the world's only leadless pacemaker to treat heart failure. And we're on track to receive FDA approval within the next two and a half weeks.”* The product already holds FDA Breakthrough Device designation, and has shown strong clinical results, including a 16.4% reduction in left ventricular end systolic volume—well above the target goal of 9.3%. Shute outlined the company's go-to-market plan, emphasizing that reimbursement is expected to begin from October 1st under the NTAP and TPT schemes, enabling an ASP of USD 45,000. The company only needs to sell around 2,200 units annually to reach USD 100 million in revenue. “We’ve got no direct competition,” he said. He also highlighted the successful completion of the FDA’s pre-approval inspection with no observations—an uncommon achievement in the medical device industry. The device, supported by data published in JAMA Cardiology, was also featured at the Heart Rhythm Society meeting in 2023. During the interim, the US commercial team will establish purchasing agreements, prepare technology committee engagements, and begin physician training for a limited market release. #EBRSystems #MedicalDevices #HeartFailureTreatment #LeadlessPacemaker #CardiacTech #FDAApproval #CRTDevice #InvestingInHealthcare #BreakthroughDevice #MedTechInnovation #JAMACardiology #HeartRhythmSociety

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Board Search Results

Board Search Results

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Board Search Results

Board Search Results

Go Ad-Free